Drug intelligence / Profile preview

SHR-1826

Development stage: Phase 2
Lead developer: Suzhou Suncadia Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

SHR-1826 is an antibody-drug conjugate (ADC) targeting c-Met, under development for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). The drug is being developed by Suzhou Suncadia Biopharmaceuticals and Jiangsu Hengrui Medicine. SHR-1826 is currently in phase II clinical trials as a combination therapy for advanced NSCLC and other advanced solid tumors. Its mechanism of action involves targeting the c-Met receptor, which is implicated in tumor growth and metastasis. The precise cytotoxic payload used in this ADC has not been publicly disclosed.

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on SHR-1826.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-1826.

Explore the full profile